NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more
NovaBridge Biosciences (NBP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.007x
Based on the latest financial reports, NovaBridge Biosciences (NBP) has a cash flow conversion efficiency ratio of 0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.15 Million) by net assets ($1.84 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NovaBridge Biosciences - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NovaBridge Biosciences's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NovaBridge Biosciences Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBridge Biosciences ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotte Chilsung Beverage
KO:005300
|
0.093x |
|
EUREKA FORBES LTD
NSE:EUREKAFORB
|
N/A |
|
Weltrend Semiconductor Inc
TW:2436
|
-0.037x |
|
Shenzhen Sunmoon Microelectronics Co. Ltd. A
SHG:688699
|
0.007x |
|
Gubra A/S
CO:GUBRA
|
1.899x |
|
Beijing Quanshi World Online Net
SHE:002995
|
-0.109x |
|
Jiangsu Allfavor Intelligent Circuits Technology CO.Ltd
SHE:300964
|
0.006x |
|
Poly Property Group Co. Limited
PINK:PHKIF
|
-0.049x |
Annual Cash Flow Conversion Efficiency for NovaBridge Biosciences (2017–2024)
The table below shows the annual cash flow conversion efficiency of NovaBridge Biosciences from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $201.16 Million | $-52.65 Million | -0.262x | -517.28% |
| 2023-12-31 | $1.72 Billion | $-72.85 Million | -0.042x | +88.43% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | -72.83% |
| 2021-12-31 | $4.59 Billion | $-973.09 Million | -0.212x | -375.29% |
| 2020-12-31 | $5.63 Billion | $433.56 Million | 0.077x | -81.94% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |